Immunosuppressant Drug Interactions Flashcards

1
Q

What are the 4 drugs that are CYP3A4 and P-gp inducers?

A

Phenytoin
Phenobarbital
Carbamazepine
Rifampin/Rifabutin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the 4 drugs that are CYP3A4 and P-gp inhibitors?

A

Macrolide antibiotics
Non-DHP CCBs (diltiazem and verapamil)
Azole antifungals
Protease inhibitors, cobicistat

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

(T/F) - Azithromycin is not considered a CYP3AR inhibitor

A

TRUE - only macrolide antibiotic that is not

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Which 3 immunosuppressant drugs should not be used concomitantly with statins?

A

CSA, SRL, and TAC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

(T/F) - Statins are inhibitors of CYP3A4

A

FALSE - they’re substrates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

(T/F) - CSA is an inhibitors of CYP3A4

A

TRUE - they’re also substrates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

(T/F) - SRL is an inducer of CYP3A4

A

FALSE - weak inhibitor (also substrates)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

(T/F) - TAC is an inhibitor of CYP3A4

A

TRUE - weak inhibitor, however

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Why are statins avoided with CSA, SRL, TAC?

A

Rhabdomyolysis can occur due to statins breaking down more muscle cells and releasing myoglobin, which causes renal injury or failure; this is because statins are substrates and CSA, SRL, and TAC are inhibitors (weak or strong) of CYP3A4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What two food and herbs interact with CSA, TAC, SRL, EVR

A

Grapefruit juice and St. John’s Wort

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Does grapefruit juice induce or inhibit CYP3A4 and P-gp?

A

Inhibits CYP3A4 and P-gp

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

In which location (hepatic or gut) does grapefruit juice inhibit CYP3A4 and P-gp? It can be both locations or different locations for each, by the way.

A

The gut for both CYP3A4 and P-gp

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the culprit in grapefruit juice?

A

Metabolite of naringin (naringenin-metabolite)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Does St. John’s Wort induce or inhibit CYP3A4 and P-gp?

A

Induces CYP3A4 and P-gp

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

In which location (hepatic or gut) does St. John’s wort affect CYP3A4 and P-gp? It can be both locations or different locations for each, by the way.

A

CYP3A4 is affected in the liver and gut

P-gp is affected in the gut

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is a severe side effect for CSA and TAC?

A

Nephrotoxicity

17
Q

What 4 drugs can increase the risk of nephrotoxicity?

A

Aminoglycosides
Vancomycin
NSAIDs
Amphotericin B

18
Q

What is the most common supratherapeutic consequence of all 4 immunosuppressants?

A

Over-immunosuppression; increasing the risk of infection

19
Q

What is the most common subtherapeutic consequence of all 4 immunosuppressants?

A

Transplant rejection

20
Q

What are the most common supratherapeutic consequence of CSA and TAC?

A

Nephrotoxic
Hypertension
Electrolyte abnormalities (increase K and Mg, decrease PO4)
Tremors - specifically TAC

21
Q

What are the most common supratherapeutic consequences of SRL and EVR?

A

Oral ulcers
Anemia
Leukopenia
Thrombocytopenia

22
Q

If CSA or TAC have been administered with enzyme inhibitors (vice versa), what approach should be taken for monitoring?

A

Monitor trough levels 2-3 days after drug initiation and manage dose adjustments appropriately

23
Q

If SRL have been administered with enzyme inhibitors (vice versa), what approach should be taken for monitoring?

A

Monitor trough levels 1 week after drug initiation and mange dose adjustments appropriately

24
Q

If EVR have been administered with enzyme inhibitors (vice versa), what approach should be taken for monitoring?

A

Monitor trough levels for 4-5 days after drug initiation and manage dose adjustments appropriately

25
Q

What monitoring approach should be taken when an enzyme inducer has been given with EVR/CSA/TAC?

A

Monitor trough levels for 4-7 days after drug initiation; increase 25% of the dose QD as needed

26
Q

Which immunosuppressant drug has a risk of obtaining progressive multifocal leukoencephalopathy (PML) as a supratherapeutic consequence?

A

Sirolimus